Sierra Oncology, Inc. Banner Image

Sierra Oncology, Inc. has reached its limit for free report views

Work for Sierra Oncology, Inc.? Upgrade Your Profile and unlock all your annual reports.

Sierra Oncology, Inc.

  • Ticker SRRA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Sierra Oncology, Inc. Logo Image
  • 51-200 Employees
  • Based in Vancouver, British Columbia
Sierra Oncology is a late stage drug development company focused on achieving the successful registration and commercialization of momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated mechanism of action that enables it to potentially address all three key drivers of myelofibrosis: anemia, constitutional symptoms and enlarged spleen. More thanMore 1,200 subjects have received momelotinib since clinical studies began in 2009, including more than 820 patients treated for myelofibrosis.
Sierra Oncology, Inc.

Most Recent Annual Report

Sierra Oncology, Inc.
MOST RECENT 2021 Annual Report and Form 10K

Report Locked. Sierra Oncology, Inc. has reached its limit for free report views.

Older/Archived Annual Reports